Availability and use of Standards in vaccine development

Author:

Avumegah Michael SelormORCID,Mattiuzzo GiadaORCID,Särnefält AnnaORCID,Page Mark,Makar Karen,Lathey Janet,Kim June,Yimer Solomon Abebe,Craig DanielleORCID,Knezevic IvanaORCID,Bernasconi Valentina,Kristiansen Paul A.,Kromann Ingrid

Abstract

AbstractReference materials are critical in assay development for calibrating and assessing their suitability. The devasting nature of the COVID-19 pandemic and subsequent proliferation of vaccine platforms and technologies has meant that there is even a greater need for standards for immunoassay development, which are critical to assess and compare vaccines’ responses. Equally important are the standards needed to control the vaccine manufacturing processes. Standardized vaccine characterization assays throughout process development are essential for a successful Chemistry, Manufacturing and Controls (CMC) strategy. In this perspective paper, we advocate for reference material incorporation into assays and their calibration to International Standards from preclinical vaccine development through control testing and provide insight into why this is necessary. We also provide information on the availability of WHO international antibody standards for CEPI-priority pathogens.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology

Reference27 articles.

1. ISO. International Standardization Organization https://www.iso.org/home.html (2023).

2. Bioanalytical Method Validation and Study Sample Analysis M10 (ICH Harmonised Guideline, 2022).

3. Expert Committee on Biological Standardization [website]. World Health Organization. https://www.who.int/groups/expert-committee-on-biological-standardization.

4. Krause P, F. T. et al. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet 12, 741–743 (2020). 396(10253).

5. Liu, M. A., Zhou, T., Sheets, R. L., Meyer, H. & Knezevic, I. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021. Emerg. Microbes Infect. 11, 384–391 (2022).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3